LUV TRZ / Ipamorelin

A research peptide blend of a long-acting acylated peptide analog and the pentapeptide ipamorelin.

Molecular Profile

Type
Peptide blend

Components

LUV TRZ

Molecular formula
C225H348N48O68
Molecular weight
~4,814 g/mol
CAS number
2023788-19-2
Sequence
Modified 39-residue acylated peptide analog; Aib at positions 2 and 13; C-terminal amide; Lys20 C20 fatty-diacid via gamma-Glu and AEEA linkers

Ipamorelin

Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
CAS number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2

Mechanism & Target Class

Combines two peptides characterized in structural studies of distinct GPCR classes. The LUV TRZ component is a long-acting, acylated peptide whose C20 fatty-diacid side chain confers reversible albumin binding, extending circulatory half-life; in cryo-EM studies it adopts an α-helical conformation in complex with class B G-protein-coupled receptors. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) characterized in structural studies of a class A G-protein-coupled receptor, where its N-terminal Aib and D-2Nal residues occupy hydrophobic receptor pockets and the Lys-NH2 terminus makes polar contacts. Because the two components are characterized at different GPCR classes, no single structural target describes the blend.

Storage & Handling

Lyophilized
≤ −20 °C with desiccant; protect from light and moisture.
Handling
The acylated peptide-analog component may aggregate if mishandled. Aliquot both components; protect from light.

References (20)

  1. Reviews

    1

    Galindo RJ, et al. (2026). Diabetes Ther

    DOI: 10.1007/s13300-025-01804-wPubMed 41196501

  2. 2

    Shiimura Y, et al. (2025). Front Mol Neurosci

    DOI: 10.3389/fnmol.2025.1549366

  3. 3

    Karagiannis T, et al. (2022). Diabetologia

    DOI: 10.1007/s00125-022-05715-4PubMed 35579691

  4. 4

    Min T, Bain SC. (2021). Diabetes Ther

    DOI: 10.1007/s13300-020-00981-0PubMed 33325008

  5. 5

    Liu QK. (2024). Front Endocrinol

    DOI: 10.3389/fendo.2024.1431292PubMed 39114288

  6. 6

    Abizaid A, Hougland JL. (2020). Trends Endocrinol Metab

    DOI: 10.1016/j.tem.2019.09.006PubMed 31636018

  7. 7

    Davis TR, et al. (2021). Open Biol

    DOI: 10.1098/rsob.210080PubMed 34315274

  8. Clinical

    8

    Gobburu JV, et al. (1999). Pharm Res

    DOI: 10.1023/a:1018955126402PubMed 10496658

  9. Primary research

    9

    Liu H, et al. (2021). Nat Commun

    DOI: 10.1038/s41467-021-26735-5

  10. 10

    Zhao F, et al. (2022). Nat Commun

    DOI: 10.1038/s41467-022-28683-0PubMed 35217653

  11. 11

    Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. (1998). Eur J Endocrinol

    DOI: 10.1530/eje.0.1390552PubMed 9849822

  12. 12

    Willard FS, et al. (2020). JCI Insight

    DOI: 10.1172/jci.insight.140532PubMed 32730231

  13. 13

    Sun B, et al. (2022). Proc Natl Acad Sci USA

    DOI: 10.1073/pnas.2116506119PubMed 35333651

  14. 14

    Samms RJ, et al. (2021). J Clin Invest

    DOI: 10.1172/JCI146353PubMed 34003802

  15. 15

    Qin J, et al. (2022). Nat Commun

    DOI: 10.1038/s41467-022-27975-9PubMed 35027551

  16. 16

    Svensson J, et al. (2000). J Endocrinol

    DOI: 10.1677/JOE.0.1650569PubMed 10828840

  17. 17

    Andersen NB, et al. (2001). Growth Horm IGF Res

    DOI: 10.1054/GHIR.2001.0239PubMed 11735244

  18. 18

    Johansen PB, et al. (1999). Growth Horm IGF Res

    DOI: 10.1054/ghir.1999.9998PubMed 10373343

  19. 19

    Venkova K, et al. (2009). J Pharmacol Exp Ther

    DOI: 10.1124/jpet.108.149211PubMed 19289567

  20. 20

    Johansen PB, et al. (1998). Xenobiotica

    DOI: 10.1080/004982598238976PubMed 9879640